Discover and read the best of Twitter Threads about #CardioOnc
Most recents (9)
#JACCCardioOnc #Tweetorial: Along the spectrum of cancer Tx, #YeSCCT has a lot to offer regarding identifying subclinical #ASCVD, excluding obstructive #cvCAD in cardiotoxicity when appropriate. #CardioOnc, as a field, can gain from incorporating CCT in practice.
🧵1/
🧵1/
#YeSCCT may identify subclinical #ASCVD in cancer patients & survivors. Reviewing previous non-gated thoracic CT scans for CAC may help identify subclinical #cvCAD and start prompt preventive Tx.
#JACCCardioOnc #CardioOnc #MedTwitter #CardioTwitter
2/
#JACCCardioOnc #CardioOnc #MedTwitter #CardioTwitter
2/
Several clinical scenarios in the context of cardiotoxicity may require ruling out obstructive #cvCAD. Cancer pts tend to have ⬆️ risk of complications from invasive procedures➡️ thrombocytopenia & hypercoagulable states. #YeSCCT may derive significant benefit. #JACCCardioOnc
3/
3/
The new epidemic: ATTR Cardiac #Amyloidosis: Current and Emerging Treatment Strategies
Follow/share this #JACCCardioOnc #Tweetorial!
🧵 1/
Follow/share this #JACCCardioOnc #Tweetorial!
🧵 1/
ATTR cardiac #amyloidosis: Tip of the iceberg - current and emerging therapies to manage and prevent #heartfailure.
#JACCCardioOnc #CardioOnc
2/
#JACCCardioOnc #CardioOnc
2/
1/ Hot-off-the-press 🔥✍🏽🗣
Precision #CardioOncology: Systems-based Perspective on Tyrosine Kinase Inhibitors & Immune Checkpoint Inhibitors
#PrecisionCardioOnc @SpringerNature
Latest manuscript w/ @MayoClinicCV @mayocvonc & edited by @AnaBaracCardio
rdcu.be/b3q0Y
Precision #CardioOncology: Systems-based Perspective on Tyrosine Kinase Inhibitors & Immune Checkpoint Inhibitors
#PrecisionCardioOnc @SpringerNature
Latest manuscript w/ @MayoClinicCV @mayocvonc & edited by @AnaBaracCardio
rdcu.be/b3q0Y
2/ 🔥✍🏽🗣
A broad spectrum of #CVD toxicities can be seen with targeted therapies or #ICIs
Toxicities of one or the other can include cardiomyopathy, HF, myocarditis, venous or arterial thrombosis, progression of atherosclerosis, QTc prolongation, or arrhythmias
#CardioOnc
A broad spectrum of #CVD toxicities can be seen with targeted therapies or #ICIs
Toxicities of one or the other can include cardiomyopathy, HF, myocarditis, venous or arterial thrombosis, progression of atherosclerosis, QTc prolongation, or arrhythmias
#CardioOnc
3/ 🔥✍🏽🗣
An eminent need is optimal risk management, surveillance, detection, and prevention
The heterogeneities of patient populations, risks, and disease spectra have complicated clinical and translation efforts
#cvPrev #PrevCardioOnc #CardioOnc
An eminent need is optimal risk management, surveillance, detection, and prevention
The heterogeneities of patient populations, risks, and disease spectra have complicated clinical and translation efforts
#cvPrev #PrevCardioOnc #CardioOnc
AMAZING blog on the important role ED providers play in recognizing the nuances that go into the managing AF in patients on ibrutinib! 👏🏻 Awesome job @iEMPharmD
One of my FAVORITE #cardioonc topics!
Summary of the 🔑 considerations 👇🏻
One of my FAVORITE #cardioonc topics!
Summary of the 🔑 considerations 👇🏻
Clinical conundrum: ibrutinib interferes with each pillar of AF management
Risk scoring tools (CHADS2VASC OR HASBLED) NOT validated in cancer patients‼️
Ibrutinib: Inhibitor 🆇 of PGP & substrate of CYP3A4➡️DDI💊
Ibrutinib ⤴️bleeding risk ALONE & only further in pts on AC
Risk scoring tools (CHADS2VASC OR HASBLED) NOT validated in cancer patients‼️
Ibrutinib: Inhibitor 🆇 of PGP & substrate of CYP3A4➡️DDI💊
Ibrutinib ⤴️bleeding risk ALONE & only further in pts on AC
Overall, difficult clinical conundrum, how do we maintain the therapeutic benefit of ibrutinib while ⤵️toxicities⚠️?
As Craig mentioned,🆕BTK inhibitors may ⬇️ risk, BUT data w/acalabrutinib still shows signals of AF risk&bleeding is on-target BTK effect so risk remains
As Craig mentioned,🆕BTK inhibitors may ⬇️ risk, BUT data w/acalabrutinib still shows signals of AF risk&bleeding is on-target BTK effect so risk remains
1/ Hot-off-the-press!
Tweetorial on Role of Angiotensin‐Converting Enzyme Inhibitors & β‐Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Pts
ahajournals.org/doi/10.1161/JA…
#CardioOnc #CardioOncology #PrevCardioOnc
@avolgman @AnaBaracCardio @DrTochiCardiOnc
Tweetorial on Role of Angiotensin‐Converting Enzyme Inhibitors & β‐Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Pts
ahajournals.org/doi/10.1161/JA…
#CardioOnc #CardioOncology #PrevCardioOnc
@avolgman @AnaBaracCardio @DrTochiCardiOnc
2/ Approx 4 million American 👩🏽👩🦳 are currently living with a hx of invasive breast ca, w/ 270,000 diagnosed within the past year. Among these 👩🏽👩🦳, 64% are aged ≥65 years. Among older 👩🏽👩🦳 survivors of breast cancer, cardiovascular disease (#CVD) is the leading cause of death
3/ Are ACEIs and β‐blockers indicated and efficacious for everyone with breast cancer? Should we offer these medications prophylactically to all patients planned for chemotherapy, radiation, or targeted therapy? #CardioOnc #CardioOncology
Check out our review on the utility of #whyCMR in the differentiation of #cardiac #mass
link.springer.com/article/10.100…
Mini-Tweetorial Follows:
#CardioOnc #cvImaging #ACCimaging
@onco_cardiology @JStojanovskaMD @MichaelCoMD
@DmitryAbramovMD @chiarabd @HeartDocSubha @larsgrowo
link.springer.com/article/10.100…
Mini-Tweetorial Follows:
#CardioOnc #cvImaging #ACCimaging
@onco_cardiology @JStojanovskaMD @MichaelCoMD
@DmitryAbramovMD @chiarabd @HeartDocSubha @larsgrowo
@onco_cardiology @JStojanovskaMD @MichaelCoMD @DmitryAbramovMD @chiarabd @HeartDocSubha @larsgrowo @SarjuGanatraMD @AnaBaracCardio @AkhilNarangMD @krychtiukmd @vass_vassiliou @DrToniyaSingh @AChoiHeart @AnkurKalraMD @adityadoc1 Incidence of Cardiac Metastases: 1.23%
Primary Cardiac Tumors 0.056%
Can be benign, malignant or pseudotumor
Primary Cardiac tumor- mostly benign
#Cardiac Mass eval: detailed clinical presentation, History, Physical Exam, #echofirst to see the tumor characteristics
Primary Cardiac Tumors 0.056%
Can be benign, malignant or pseudotumor
Primary Cardiac tumor- mostly benign
#Cardiac Mass eval: detailed clinical presentation, History, Physical Exam, #echofirst to see the tumor characteristics
@onco_cardiology @JStojanovskaMD @MichaelCoMD @DmitryAbramovMD @chiarabd @HeartDocSubha @larsgrowo @SarjuGanatraMD @AnaBaracCardio @AkhilNarangMD @krychtiukmd @vass_vassiliou @DrToniyaSingh @AChoiHeart @AnkurKalraMD @adityadoc1 @JoaoLCavalcante @almasthela @iamritu @DrMarthaGulati @hvanspall @venkmurthy @aayshacader @IAmDrIbrahim @poojaotherwise @mswami001 #whyCMR helps with high accuracy and able to provide the diagnosis in cases of cardiac #mass
#whyCMR eval:
Cine imaging
T1 and T2 weight imaging with and without FS
First Pass Perfusion
EGE, LGE & post-Gad T1W imaging
@fabrizioricci @MasriAhmadMD @cshenoy3 @afshinfarzan
#whyCMR eval:
Cine imaging
T1 and T2 weight imaging with and without FS
First Pass Perfusion
EGE, LGE & post-Gad T1W imaging
@fabrizioricci @MasriAhmadMD @cshenoy3 @afshinfarzan
1/ Preventive Cardio-Oncology Tutorial #PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
“The time has come for cardiovascular disease (CVD) prevention to play a more prominent role in cardio-oncology.”
tinyurl.com/PrevCardioOncT…
“The time has come for cardiovascular disease (CVD) prevention to play a more prominent role in cardio-oncology.”
tinyurl.com/PrevCardioOncT…
2/ “A myriad of novel cardiotoxic chemotherapeutic & immunotherapeutic drugs are continuously being developed in #Oncology, with diverse cardiovascular (CV) effects.”
tinyurl.com/PrevCardioOncT…
#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
tinyurl.com/PrevCardioOncT…
#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
3/ Chest radiation “can result in accelerated atherosclerosis, pericardial disease, valve disease, conduction abnormalities, & cardiomyopathies.”
tinyurl.com/PrevCardioOncT…
#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
tinyurl.com/PrevCardioOncT…
#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
Here goes it! 🎙
Okay for all those non-oncology experts walking into this situation, let’s take a few steps back 🦶 and give a background on ibrutinib 👩🏫📜
Okay for all those non-oncology experts walking into this situation, let’s take a few steps back 🦶 and give a background on ibrutinib 👩🏫📜
Ibrutinib (Ibruvica®️) is a first in class ORAL 💊 Bruton tyrosine kinase (BTK) inhibitor,
Used for the treatment of a variety of B-cell lymphomas and Waldenstrom macroglobulinemia 🧬
Used for the treatment of a variety of B-cell lymphomas and Waldenstrom macroglobulinemia 🧬
Ibrutinub was a paradigm shift in the management of patients with CLL as initial or relapsed refractory cases
✅improved progression-free survival, ✅overall response rates, and ✅ overall survival
This was compared w/ ofatumumab (AKA rituximabs cousin) & ⚠️ chlorambucil ⚠️
✅improved progression-free survival, ✅overall response rates, and ✅ overall survival
This was compared w/ ofatumumab (AKA rituximabs cousin) & ⚠️ chlorambucil ⚠️
Hi guys! I’m kind of in the mood to give a talk this night. So why not talk about #CardioOnc & #whyCMR? #CardioTwitter #JACCCardioOnc
We started our small “shop” in mid 2013, with the help of @DipanJShah, he allowed me to start a small CMR practice at @HMethodistCV. I did that until we got #CardsRads right, then @XRayDUG supported me and I was able to practice CMR at MD Anderson, then our volumes have been ⬆️
In 2017, when we got +300, I got so happy, that we wrote about our CMR experience in a major cancer center. Jon Weinsaft had a great practice at MSK already, so we couldn’t claim it was the first CMR practice in a major cancer center, still we were very happy about it.
